Abstract
Hepatitis E virus (HEV) can cause chronic infection and liver cirrhosis in immunocompromised individuals. The frequency and clinical importance of HEV was studied retrospectively in a cohort of 236 Swedish allogeneic hematopoietic stem cell transplantation (HSCT) recipients. In blood samples collected at 6 months after HSCT, HEV RNA was identified in 8/236 (3.4%) patients, and 11/236 (4.7%) patients had detectable anti-HEV IgG and/or IgM, eight of whom were HEV RNA negative. Two of the patients with positive HEV RNA died with ongoing signs of hepatitis: one of acute liver and multiple organ failure, the other of unrelated causes. The remaining six patients with HEV RNA had cleared the infection at 7–24 (median 8.5) months after HSCT. HEV infection was associated with elevated alanine aminotransferase at 6 months after HSCT (OR 15, 1.3–174, p = 0.03). Active graft-versus-host disease of the liver at 6 months after HSCT was present in 3/8 (38%) patients with HEV RNA, but was not significantly associated with HEV infection. In conclusion, HEV infection is an important differential diagnosis in patients with elevated liver enzymes after HSCT. Although spontaneous clearance was common, the clinical course may be severe.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kamar N, Izopet J, Pavio N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Prim. 2017;3:17086. https://doi.org/10.1038/nrdp.2017.86.
Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766–73. https://doi.org/10.1016/s0140-6736(14)61034-5.
Koenecke C, Pischke S, Beutel G, Ritter U, Ganser A, Wedemeyer H, et al. Hepatitis E virus infection in a hematopoietic stem cell donor. Bone Marrow Transplant. 2014;49:159–60. https://doi.org/10.1038/bmt.2013.148.
Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Kruger DH, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol. 2012;56:500–2. https://doi.org/10.1016/j.jhep.2011.06.021.
Guillois Y, Abravanel F, Miura T, Pavio N, Vaillant V, Lhomme S, et al. High proportion of asymptomatic infections in an outbreak of hepatitis E associated with a spit-roasted piglet, France, 2013. Clin Infect Dis. 2016;62:351–7. https://doi.org/10.1093/cid/civ862.
Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358:811–7. https://doi.org/10.1056/NEJMoa0706992.
Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361:1025–7. https://doi.org/10.1056/NEJMc0903778.
Ollier L, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med. 2009;150:430–1.
Versluis J, Pas SD, Agteresch HJ, de Man RA, Maaskant J, Schipper ME, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:1079–86. https://doi.org/10.1182/blood-2013-03-492363.
Koenecke C, Pischke S, Heim A, Raggub L, Bremer B, Raupach R, et al. Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country? Transpl Infect Dis. 2012;14:103–6. https://doi.org/10.1111/j.1399-3062.2011.00702.x.
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A, et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transpl. 2011;17:1688–97. https://doi.org/10.1016/j.bbmt.2011.05.001.
Torlen J, Ringden O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, et al. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101:1417–25. https://doi.org/10.3324/haematol.2016.149294.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56. https://doi.org/10.1016/j.bbmt.2005.09.004.
Norder H, Karlsson M, Mellgren A, Konar J, Sandberg E, Lasson A, et al. Diagnostic performance of five assays for anti-hepatitis E virus IgG and IgM in a large cohort study. J Clin Microbiol. 2016;54:549–55. https://doi.org/10.1128/jcm.02343-15.
Roth A, Lin J, Magnius L, Karlsson M, Belak S, Widen F, et al. Markers for ongoing or previous hepatitis E virus infection are as common in wild ungulates as in humans in Sweden. Viruses. 2016;8. https://doi.org/10.3390/v8090259.
Pagano M, Gauvreau K. Principles of Biostatistics, 2nd edition. Pacific Grove, CA: Duxbury; 2000.
Sheskin DJ. Handbook of parametric and nonparametric statistical procedures, 4th edition. Boca Raton, FL: Chapman & Hall/ CRC; 2004.
Willemse SB, Bezuur DL, Blom P, Kneppers E, Verheij J, Zaaijer HL, et al. Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients. Bone Marrow Transplant. 2017;52:622–4. https://doi.org/10.1038/bmt.2016.327.
Tang FF, Mo XD, Wang Y, Yan CH, Chen YH, Chen H, et al. Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. Br J Haematol. 2019;184:788–96. https://doi.org/10.1111/bjh.15672.
Abravanel F, Mansuy JM, Huynh A, Kamar N, Alric L, Peron JM, et al. Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol. 2012;54:152–5. https://doi.org/10.1016/j.jcv.2012.02.015.
Reekie I, Irish D, Ijaz S, Fox T, Bharucha T, Griffiths P, et al. Hepatitis E infection in stem cell and solid organ transplantpatients: a cross-sectional study: the importance of HEV RNA screening in peri-transplant period. J Clin Virol. 2018;107:1–5. https://doi.org/10.1016/j.jcv.2018.07.011.
Carre M, Thiebaut-Bertrand A, Larrat S, Leroy V, Pouzol P, Sturm N, et al. Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation. Bone Marrow Transplant. 2017;52:643–5. https://doi.org/10.1038/bmt.2016.337.
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, et al. The burden of hepatitis E among patients with haematological malignancies: a retrospective European cohort study. J Hepatol. 2019;71:465–72. https://doi.org/10.1016/j.jhep.2019.04.022.
Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol. 2012;18:1851–60. https://doi.org/10.3748/wjg.v18.i16.1851.
Donnelly MC, Scobie L, Crossan CL, Dalton H, Hayes PC, Simpson KJ. Review article: hepatitis E—a concise review of virology, epidemiology, clinical presentation and therapy. Aliment Pharmacol Ther. 2017;46:126–41. https://doi.org/10.1111/apt.14109.
Wahren B, Gahrton G, Linde A, Ljungman P, Lonnqvist B, Ringden O, et al. Transfer and persistence of viral antibody-producing cells in bone marrow transplantation. J Infect Dis. 1984;150:358–65. https://doi.org/10.1093/infdis/150.3.358.
Baylis SA, Gartner T, Nick S, Ovemyr J, Blumel J. Occurrence of hepatitis E virus RNA in plasma donations from Sweden, Germany and the United States. Vox Sang. 2012;103:89–90. https://doi.org/10.1111/j.1423-0410.2011.01583.x.
Thom K, Gilhooly P, McGowan K, Malloy K, Jarvis LM, Crossan C, et al. Hepatitis E virus (HEV) in Scotland: evidence of recent increase in viral circulation in humans. Euro Surveill: Bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2018;23. https://doi.org/10.2807/1560-7917.Es.2018.23.12.17-00174.
Boland F, Martinez A, Pomeroy L, O’Flaherty N. Blood donor screening for hepatitis E virus in the European Union. Transfus Med Hemother. 2019;46:95–103. https://doi.org/10.1159/000499121.
Norder H, Galli C, Magnil E, Sikora P, Ekvarn E, Nystrom K, et al. Hepatitis E virus genotype 3 genomes from RNA-positive but serologically negative plasma donors have CUG as the Start Codon for ORF3. Intervirology. 2018;61:96–103. https://doi.org/10.1159/000491926.
Norder H, Sundqvist L, Magnusson L, Ostergaard Breum S, Lofdahl M, Larsen LE, et al. Endemic hepatitis E in two Nordic countries. Euro Surveill: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2009;14:pii: 19211.
Boxman ILA, Jansen CCC, Hagele G, Zwartkruis-Nahuis A, Tijsma ASL, Vennema H. Monitoring of pork liver and meat products on the Dutch market for the presence of HEV RNA. Int J Food Microbiol. 2019;296:58–64. https://doi.org/10.1016/j.ijfoodmicro.2019.02.018.
Wang H, Castillo-Contreras R, Saguti F, Lopez-Olvera JR, Karlsson M, Mentaberre G, et al. Genetically similar hepatitis E virus strains infect both humans and wild boars in the Barcelona area, Spain, and Sweden. Transbound Emerg Dis. 2019;66:978–85. https://doi.org/10.1111/tbed.13115.
Agency EM. Reflection paper on viral safety of plasma-derived medicinal products with respect to hepatitis E virus. London: European Medicines Agency; 2016.
EASL. Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256–71. https://doi.org/10.1016/j.jhep.2018.03.005.
Acknowledgements
We thank Stephan Mielke for critically reading the paper and giving valuable comments.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Swartling, L., Nordén, R., Samuelsson, E. et al. Hepatitis E virus is an infrequent but potentially serious infection in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 55, 1255–1263 (2020). https://doi.org/10.1038/s41409-020-0823-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-0823-7
This article is cited by
-
HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party
Bone Marrow Transplantation (2022)